These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Early predictors of colectomy and long-term maintenance of remission in ulcerative colitis patients treated using anti-tumour necrosis factor therapy. Subramaniam K, Richardson A, Dodd J, Platten J, Shadbolt B, Pavli P. Intern Med J; 2014 May; 44(5):464-70. PubMed ID: 24612209 [Abstract] [Full Text] [Related]
12. Efficacy and safety of Fufangkushen colon-coated capsule in the treatment of ulcerative colitis compared with mesalazine: a double-blinded and randomized study. Gong Y, Zha Q, Li L, Liu Y, Yang B, Liu L, Lu A, Lin Y, Jiang M. J Ethnopharmacol; 2012 Jun 01; 141(2):592-8. PubMed ID: 21911045 [Abstract] [Full Text] [Related]
14. Curcumin in Combination With Mesalamine Induces Remission in Patients With Mild-to-Moderate Ulcerative Colitis in a Randomized Controlled Trial. Lang A, Salomon N, Wu JC, Kopylov U, Lahat A, Har-Noy O, Ching JY, Cheong PK, Avidan B, Gamus D, Kaimakliotis I, Eliakim R, Ng SC, Ben-Horin S. Clin Gastroenterol Hepatol; 2015 Aug 01; 13(8):1444-9.e1. PubMed ID: 25724700 [Abstract] [Full Text] [Related]
15. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. Sandborn WJ, Regula J, Feagan BG, Belousova E, Jojic N, Lukas M, Yacyshyn B, Krzeski P, Yeh CH, Messer CA, Hanauer SB. Gastroenterology; 2009 Dec 01; 137(6):1934-43.e1-3. PubMed ID: 19766640 [Abstract] [Full Text] [Related]
16. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Lichtenstein GR, Kamm MA, Boddu P, Gubergrits N, Lyne A, Butler T, Lees K, Joseph RE, Sandborn WJ. Clin Gastroenterol Hepatol; 2007 Jan 01; 5(1):95-102. PubMed ID: 17234558 [Abstract] [Full Text] [Related]
17. Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis. Sandborn WJ, Korzenik J, Lashner B, Leighton JA, Mahadevan U, Marion JF, Safdi M, Sninsky CA, Patel RM, Friedenberg KA, Dunnmon P, Ramsey D, Kane S. Gastroenterology; 2010 Apr 01; 138(4):1286-96, 1296.e1-3. PubMed ID: 20064514 [Abstract] [Full Text] [Related]
18. Once-daily versus multiple-daily mesalamine for patients with ulcerative colitis: a meta-analysis. Tong JL, Huang ML, Xu XT, Qiao YQ, Ran ZH. J Dig Dis; 2012 Apr 01; 13(4):200-7. PubMed ID: 22435504 [Abstract] [Full Text] [Related]
20. Strategies in maintenance for patients receiving long-term therapy (SIMPLE): a study of MMX mesalamine for the long-term maintenance of quiescent ulcerative colitis. Kane S, Katz S, Jamal MM, Safdi M, Dolin B, Solomon D, Palmen M, Barrett K. Inflamm Bowel Dis; 2012 Jun 01; 18(6):1026-33. PubMed ID: 21837775 [Abstract] [Full Text] [Related] Page: [Next] [New Search]